Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Tour of Denmark: Wout van Aert seals overall victory as Rasmus Søjberg Pedersen wins crash-marred stage 5 sprint

Visma-Lease a Bike rider takes second overall title in Danish stage race after 2018 victory

Cycling News

NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

Barchart

Tour of Denmark: Wout van Aert scores hat-trick on stage 3 with a win on wet and wild queen stage

Lukaš Kubiš retains second place on GC with runner-up finish to race leader

Cycling News

From analysis to the latest developments in health,
read the most diverse news in one place.

New Research Finds Semaglutide Users Held Lower Calorie Intake For More Than A Year

A 60-week Penn trial found semaglutide users ate 24% to 30% fewer calories than placebo, even after appetite suppression faded. Here is the detail.

Medical Daily

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

The Economic Times

Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds

Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds

The Independent UK

Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing

The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…

The Economic Times

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone…

The Economic Times

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion…

The Economic Times

Once-a-week insulin launched in India, but doctors say it won't replace daily shots for all

India now offers Awiqli, a new once-weekly basal insulin for diabetes patients. This drug reduces annual injections from 365 to just 52 for many individuals. Experts suggest Awiqli is an additional option, not a complete replacement for daily insulin. It is best suited for patients who still produce some insulin…

The Economic Times

A Shot Every Two Weeks Instead of Weekly: New GLP-1 Drug Shows Strong Trial Results

A new biweekly GLP-1 drug called bofanglutide showed strong blood sugar and weight loss results in a Phase 2b trial. Monthly injectables and oral pills are also in the pipeline.

Medical Daily

Novo Nordisk launches once-weekly basal insulin 'Awiqli' in India as diabetes rates increase

Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to daily injections for diabetes patients. Awiqli aims to reduce barriers to insulin initiation, which is often delayed in India. The Indian insulin market is projected to grow significantly in…

The Economic Times

Wegovy weight-loss pill goes on sale on UK high street and online pharmacies

Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?

The Independent UK

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay.

The Independent UK

Everything you need to know about the new Wegovy pill – and whether you should take it or not

LET’S UNPACK THAT: With massive demand for the GLP-1 tablets as they are approved for use in the UK, Helen Coffey asks experts how they differ from the jab and whether they are the next big step in the weight-loss revolution

TechRadar

Novo Nordisk reveals cyberattack: Ozempic and Wegovy maker says clinical trials data breached

The company says the data is pseudonymous and apparently can't be linked to actual people.

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Independent UK

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

Medical Daily

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

Medical Daily

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

Diabetes care is entering a new era in San Antonio as the Wegovy pill and expanded Medicare coverage offer new hope for preventing and managing diabetes in one of America's hardest-hit cities.

MarketBeat

5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

The Economic Times

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to market by as much as two-thirds. Its center in Bengaluru, India, is becoming crucial for global drug preparations.

MarketBeat

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.